Drug Profile


Alternative Names: BIBR 363

Latest Information Update: 14 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Class Antihypertensives; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Congestive heart failure in Germany (PO)
  • 14 Jun 2001 No-Development-Reported for Hypertension in Germany (PO)
  • 19 Aug 1997 Investigation in Congestive heart failure in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top